The Model Based Approach: A Better Way To Forecast Enrollment

The clinical phases of drug development represent the eagerly awaited period where after several years of research and development, promising treatments become available for volunteer patients. The stakes at this stage are high: While less than two-thirds of Phase 3 trials are successful [1], they represent the most costly and time-consuming period of drug development. One of the critical questions facing trial planners is: "Can we recruit the required number of patients (e.g. 1000) within the assigned time (e.g. 25 months)?" Find out if this is possible in the available white paper.

To learn more about Cytel, visit their Clinical Leader page.